Novo CEO to depart as obesity drugmaker’s challenges rise
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have lost more than half their value over the past 12 months.
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have lost more than half their value over the past 12 months.
